What Happened — The Announcement Explained
What Happened — The Announcement Explained
For the millions of patients who relied on physician-prescribed peptide therapies — and the clinicians who prescribed them — 2023 was a hard year. The FDA placed 19 widely used peptides on its Category 2 restricted list, effectively ending licensed compounding pharmacies' ability to prepare and dispense them. BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, and more than a dozen others disappeared from legitimate clinical supply chains almost overnight.
On February 27, 2026, that began to change. During his appearance on Episode #2461 of the Joe Rogan Experience, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of those 19 restricted peptides are expected to move from Category 2 back to Category 1 status — restoring the legal pathway for licensed compounding pharmacies to prepare them under physician prescription.
The announcement covers compounds studied for tissue repair, immune modulation, metabolic health, cognitive function, and longevity. BPC-157 — arguably the most widely recognized peptide in clinical practice and in the biohacking community — is among those expected to regain legal compounding status.
This is meaningful news. But it comes with an important caveat that every patient deserves to understand: as of this writing, the FDA has not yet published its formal updated list. The announcement signals what is coming. The formal reclassification is still pending.
For the millions of patients who relied on physician-prescribed peptide therapies — and the clinicians who prescribed them — 2023 was a hard year. The FDA placed 19 widely used peptides on its Category 2 restricted list, effectively ending licensed compounding pharmacies' ability to prepare and dispense them. BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, and more than a dozen others disappeared from legitimate clinical supply chains almost overnight.
On February 27, 2026, that began to change. During his appearance on Episode #2461 of the Joe Rogan Experience, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of those 19 restricted peptides are expected to move from Category 2 back to Category 1 status — restoring the legal pathway for licensed compounding pharmacies to prepare them under physician prescription.
The announcement covers compounds studied for tissue repair, immune modulation, metabolic health, cognitive function, and longevity. BPC-157 — arguably the most widely recognized peptide in clinical practice and in the biohacking community — is among those expected to regain legal compounding status.
This is meaningful news. But it comes with an important caveat that every patient deserves to understand: as of this writing, the FDA has not yet published its formal updated list. The announcement signals what is coming. The formal reclassification is still pending.
How We Got Here — The FDA Category System and the 2023 Restriction
How We Got Here — The FDA Category System and the 2023 Restriction
To understand what the 2026 reclassification means, you need to understand how the FDA regulates compounded medications. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can legally prepare individualized medications for patients with valid prescriptions — provided the bulk drug substance they use meets one of three criteria: it appears on the FDA's Category 1 list of approved bulk substances, it has a USP/NF monograph, or it is a component of an FDA-approved drug.
Category 2 is where compounds go when the FDA has determined they cannot be used in compounding — typically because the agency has identified safety signals, insufficient data, or both. In 2023, the FDA moved 19 popular peptides to Category 2, citing concerns about immunogenicity risk, peptide-related impurities, and limited human safety data. The immediate effect: compounding pharmacies across the United States were required to stop preparing these compounds for patients.
The unintended consequence was predictable. Patient demand did not disappear — it migrated to the gray market. Online vendors selling peptides labeled "for research use only" filled the void, with no pharmaceutical oversight, no quality controls, no standardized dosing, and no physician involvement. The restrictions intended to improve patient safety created a market that was, in many ways, less safe.
This dynamic became a central argument for reversing the restriction. As Kennedy himself acknowledged during the February 2026 announcement, the Category 2 designations effectively created and accelerated the very gray market they were designed to prevent. The reclassification is, in part, a recognition that regulated access through licensed pharmacies — with USP 797 and 795 compliance, sterility testing, and pharmaceutical-grade raw materials — is safer than the alternative.
To understand what the 2026 reclassification means, you need to understand how the FDA regulates compounded medications. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can legally prepare individualized medications for patients with valid prescriptions — provided the bulk drug substance they use meets one of three criteria: it appears on the FDA's Category 1 list of approved bulk substances, it has a USP/NF monograph, or it is a component of an FDA-approved drug.
Category 2 is where compounds go when the FDA has determined they cannot be used in compounding — typically because the agency has identified safety signals, insufficient data, or both. In 2023, the FDA moved 19 popular peptides to Category 2, citing concerns about immunogenicity risk, peptide-related impurities, and limited human safety data. The immediate effect: compounding pharmacies across the United States were required to stop preparing these compounds for patients.
The unintended consequence was predictable. Patient demand did not disappear — it migrated to the gray market. Online vendors selling peptides labeled "for research use only" filled the void, with no pharmaceutical oversight, no quality controls, no standardized dosing, and no physician involvement. The restrictions intended to improve patient safety created a market that was, in many ways, less safe.
This dynamic became a central argument for reversing the restriction. As Kennedy himself acknowledged during the February 2026 announcement, the Category 2 designations effectively created and accelerated the very gray market they were designed to prevent. The reclassification is, in part, a recognition that regulated access through licensed pharmacies — with USP 797 and 795 compliance, sterility testing, and pharmaceutical-grade raw materials — is safer than the alternative.
Which Peptides Are Expected to Return — and What the Science Says
Which Peptides Are Expected to Return — and What the Science Says
Based on the February 2026 announcement and analysis from compounding pharmacy associations and regulatory experts, approximately 14 of the 19 restricted peptides are expected to return to Category 1 status. The following are among those anticipated to regain legal compounding access:
BPC-157 (Body Protection Compound-157) — Extensively studied in preclinical models for gut healing, musculoskeletal repair, tendon recovery, and anti-inflammatory effects. One of the most widely used peptides in physician-supervised clinical practice before the 2023 restriction.
Thymosin Alpha-1 — An immune-modulating peptide approved as a pharmaceutical product in more than 30 countries for applications including hepatitis B, hepatitis C, and immune adjuvant therapy in oncology.
TB-500 (Thymosin Beta-4 Fragment) — Studied for tissue repair, wound healing, and reduction of inflammation. Often prescribed alongside BPC-157 for musculoskeletal recovery protocols.
CJC-1295 — A growth hormone-releasing hormone (GHRH) analog that stimulates natural growth hormone production. Frequently used in protocols targeting body composition, metabolic health, and sleep quality.
Ipamorelin — A selective growth hormone secretagogue with a favorable side effect profile. Commonly paired with CJC-1295 in physician-supervised longevity and body composition protocols.
AOD-9604 — A peptide fragment studied for fat metabolism and lipolysis without the blood sugar or growth hormone side effects associated with full GH therapy.
GHK-Cu (Copper Peptide, injectable) — Studied for collagen synthesis, tissue remodeling, and cellular regeneration. Used in wound healing and longevity protocols.
Selank and Semax — Neuropeptides studied for anxiolytic effects, cognitive function, BDNF enhancement, and stress resilience.
KPV — An anti-inflammatory peptide studied for gut barrier integrity, with potential applications in inflammatory bowel conditions.
MOTS-C — A mitochondrial-derived peptide studied for metabolic regulation, insulin sensitivity, and healthy aging.
It is important to be precise about what Category 1 reclassification means—and what it does not. Category 1 status allows licensed compounding pharmacies to prepare a compound for patients under a physician's prescription. It does not mean these peptides are FDA-approved drugs. FDA approval requires successful completion of multi-phase clinical trials demonstrating safety and efficacy for a specific indication — a process that none of these peptides have completed for human use in the United States. Physician prescription, pharmacy-grade compounding, and clinical supervision remain essential requirements. These are not over-the-counter products.
Approximately five of the original 19 peptides are expected to remain on the restricted list — likely those with more limited safety profiles, higher misuse potential, or closer proximity to existing FDA-approved drug categories.
Based on the February 2026 announcement and analysis from compounding pharmacy associations and regulatory experts, approximately 14 of the 19 restricted peptides are expected to return to Category 1 status. The following are among those anticipated to regain legal compounding access:
BPC-157 (Body Protection Compound-157) — Extensively studied in preclinical models for gut healing, musculoskeletal repair, tendon recovery, and anti-inflammatory effects. One of the most widely used peptides in physician-supervised clinical practice before the 2023 restriction.
Thymosin Alpha-1 — An immune-modulating peptide approved as a pharmaceutical product in more than 30 countries for applications including hepatitis B, hepatitis C, and immune adjuvant therapy in oncology.
TB-500 (Thymosin Beta-4 Fragment) — Studied for tissue repair, wound healing, and reduction of inflammation. Often prescribed alongside BPC-157 for musculoskeletal recovery protocols.
CJC-1295 — A growth hormone-releasing hormone (GHRH) analog that stimulates natural growth hormone production. Frequently used in protocols targeting body composition, metabolic health, and sleep quality.
Ipamorelin — A selective growth hormone secretagogue with a favorable side effect profile. Commonly paired with CJC-1295 in physician-supervised longevity and body composition protocols.
AOD-9604 — A peptide fragment studied for fat metabolism and lipolysis without the blood sugar or growth hormone side effects associated with full GH therapy.
GHK-Cu (Copper Peptide, injectable) — Studied for collagen synthesis, tissue remodeling, and cellular regeneration. Used in wound healing and longevity protocols.
Selank and Semax — Neuropeptides studied for anxiolytic effects, cognitive function, BDNF enhancement, and stress resilience.
KPV — An anti-inflammatory peptide studied for gut barrier integrity, with potential applications in inflammatory bowel conditions.
MOTS-C — A mitochondrial-derived peptide studied for metabolic regulation, insulin sensitivity, and healthy aging.
It is important to be precise about what Category 1 reclassification means—and what it does not. Category 1 status allows licensed compounding pharmacies to prepare a compound for patients under a physician's prescription. It does not mean these peptides are FDA-approved drugs. FDA approval requires successful completion of multi-phase clinical trials demonstrating safety and efficacy for a specific indication — a process that none of these peptides have completed for human use in the United States. Physician prescription, pharmacy-grade compounding, and clinical supervision remain essential requirements. These are not over-the-counter products.
Approximately five of the original 19 peptides are expected to remain on the restricted list — likely those with more limited safety profiles, higher misuse potential, or closer proximity to existing FDA-approved drug categories.
For your longevity goals
Support healthy aging with a plan built around you
For your longevity goals
Support healthy aging with a plan built around you
For your longevity goals
Support healthy aging with a plan built around you
For your longevity goals
Support healthy aging with a plan built around you
Why Physician Oversight Matters More After This Announcement, Not Less
Why Physician Oversight Matters More After This Announcement, Not Less
There is a version of this story that is told as a liberation narrative: the FDA is stepping back, peptides are returning, and patients can now access what was taken from them. That framing is partially accurate — and potentially dangerous.
The reclassification creates a legal pathway for physician-supervised, pharmacy-compounded peptide access. It does not validate the gray-market sourcing that many patients turned to during the restriction period. It does not mean these compounds are safe to self-administer without clinical evaluation. And it does not eliminate the need for the one thing that protects patients more than any regulatory change: a physician who understands their biology, orders the appropriate labs, determines clinical indication, and monitors their response.
For patients who obtained peptides through unregulated online vendors during the restriction period, the reclassification presents an opportunity to transition to legitimate, supervised care. The quality difference between pharmaceutical-grade compounded peptides from a PCAB-accredited pharmacy and "research use only" products sourced online is not trivial. Standardized dosing, sterility certification, and verified purity are not bureaucratic formalities — they are the difference between a clinical tool and an unknown substance.
At AgeMD, every peptide protocol begins the same way any other clinical program does: with a comprehensive physician evaluation, a review of your biomarker panel, and a protocol built around your specific clinical picture. Your physician determines the clinical indication. Your pharmacy is FDA-registered. Your protocol is supervised throughout. The reclassification makes this pathway accessible again. It does not make the physician's step optional.
Compounded medications are prepared by an FDA-registered pharmacy. Compounded drugs are not FDA-approved drug products. Individual results may vary. This is not medical advice. Consult a licensed physician before starting any treatment program.
There is a version of this story that is told as a liberation narrative: the FDA is stepping back, peptides are returning, and patients can now access what was taken from them. That framing is partially accurate — and potentially dangerous.
The reclassification creates a legal pathway for physician-supervised, pharmacy-compounded peptide access. It does not validate the gray-market sourcing that many patients turned to during the restriction period. It does not mean these compounds are safe to self-administer without clinical evaluation. And it does not eliminate the need for the one thing that protects patients more than any regulatory change: a physician who understands their biology, orders the appropriate labs, determines clinical indication, and monitors their response.
For patients who obtained peptides through unregulated online vendors during the restriction period, the reclassification presents an opportunity to transition to legitimate, supervised care. The quality difference between pharmaceutical-grade compounded peptides from a PCAB-accredited pharmacy and "research use only" products sourced online is not trivial. Standardized dosing, sterility certification, and verified purity are not bureaucratic formalities — they are the difference between a clinical tool and an unknown substance.
At AgeMD, every peptide protocol begins the same way any other clinical program does: with a comprehensive physician evaluation, a review of your biomarker panel, and a protocol built around your specific clinical picture. Your physician determines the clinical indication. Your pharmacy is FDA-registered. Your protocol is supervised throughout. The reclassification makes this pathway accessible again. It does not make the physician's step optional.
Compounded medications are prepared by an FDA-registered pharmacy. Compounded drugs are not FDA-approved drug products. Individual results may vary. This is not medical advice. Consult a licensed physician before starting any treatment program.
What Patients Should Do Now — The Practical Roadmap
What Patients Should Do Now — The Practical Roadmap
Given that the formal FDA reclassification has been announced but not yet officially published, patients and physicians are in a period of transition. Here is the practical guidance for navigating it:
If you are currently sourcing peptides from gray-market or "research use only" vendors:
The reclassification provides a path to legitimate, physician-supervised access. Now is the time to establish a clinical relationship with a qualified physician who understands peptide therapy — not to continue or escalate unregulated sourcing in response to the announcement. The legal and quality arguments for waiting for the formal reclassification and transitioning to pharmacy-compounded products are strong.
If you are an existing patient with a prior prescription history:
Your physician should be monitoring the FDA's formal publication and will advise you on when compounding pharmacy access is restored for specific compounds. Do not attempt to restart a prior protocol without a current physician evaluation — your clinical picture and goals may have changed, and your physician needs to reassess.
If you are new to peptide therapy and have been considering it:
The reclassification changes the legal landscape but does not change the clinical process. Start with a physician evaluation, a comprehensive biomarker panel, and a protocol built around your specific biology. A physician who prescribes a peptide protocol without reviewing your labs is not the right starting point, regardless of what the regulatory environment looks like.
What to look for in a compounding pharmacy when access is formally restored:
PCAB (Pharmacy Compounding Accreditation Board) accreditation
USP 797 and 795 compliance for sterile and non-sterile compounding
Certificate of Analysis (COA) available for all compounds
Verified raw material sourcing with third-party purity testing
Physician prescription required — not optional
AgeMD partners with FDA-registered, accredited compounding pharmacies. When BPC-157 and related compounds are formally returned to Category 1 status, AgeMD physicians will evaluate the clinical indication on a patient-by-patient basis and prescribe accordingly.
Given that the formal FDA reclassification has been announced but not yet officially published, patients and physicians are in a period of transition. Here is the practical guidance for navigating it:
If you are currently sourcing peptides from gray-market or "research use only" vendors:
The reclassification provides a path to legitimate, physician-supervised access. Now is the time to establish a clinical relationship with a qualified physician who understands peptide therapy — not to continue or escalate unregulated sourcing in response to the announcement. The legal and quality arguments for waiting for the formal reclassification and transitioning to pharmacy-compounded products are strong.
If you are an existing patient with a prior prescription history:
Your physician should be monitoring the FDA's formal publication and will advise you on when compounding pharmacy access is restored for specific compounds. Do not attempt to restart a prior protocol without a current physician evaluation — your clinical picture and goals may have changed, and your physician needs to reassess.
If you are new to peptide therapy and have been considering it:
The reclassification changes the legal landscape but does not change the clinical process. Start with a physician evaluation, a comprehensive biomarker panel, and a protocol built around your specific biology. A physician who prescribes a peptide protocol without reviewing your labs is not the right starting point, regardless of what the regulatory environment looks like.
What to look for in a compounding pharmacy when access is formally restored:
PCAB (Pharmacy Compounding Accreditation Board) accreditation
USP 797 and 795 compliance for sterile and non-sterile compounding
Certificate of Analysis (COA) available for all compounds
Verified raw material sourcing with third-party purity testing
Physician prescription required — not optional
AgeMD partners with FDA-registered, accredited compounding pharmacies. When BPC-157 and related compounds are formally returned to Category 1 status, AgeMD physicians will evaluate the clinical indication on a patient-by-patient basis and prescribe accordingly.
What This Means for the Future of Longevity Medicine
What This Means for the Future of Longevity Medicine
The February 2026 announcement is not just a regulatory correction. It reflects a broader shift in how HHS under Secretary Kennedy is approaching the intersection of patient access, clinical innovation, and regulatory oversight. For patients who have been tracking the longevity medicine space — who understand the difference between reactive disease management and proactive optimization — this is a meaningful signal.
The compounds returning to legal compounding status have decades of preclinical research and growing clinical evidence. Their restriction created an access gap that was filled by an unregulated market that served neither patient safety nor clinical outcomes. The reclassification does not resolve all scientific questions about these compounds — the lack of large-scale human trials remains a real limitation that physicians and patients should take seriously. But it does restore the appropriate setting for those questions to be answered: physician-supervised clinical practice, pharmacy-grade compounding, and longitudinal patient monitoring.
For patients waiting for access to physician-prescribed peptide protocols, the trajectory is clear. For those who have been using unregulated products and are now reconsidering, the path to safer access is becoming available. And for the broader project of longevity medicine — building a clinical practice that optimizes biology rather than reacting to disease — the return of these compounds to legitimate access is a step in the right direction.
AgeMD physicians approach every program the same way: with your biomarker panel, your clinical history, and a protocol built around what is actually happening in your body. When BPC-157 and related compounds formally return to legal compounding status, that will not change. What changes is that the tool is available again — used properly, under physician supervision, from a pharmacy that meets the quality standards your health deserves. Learn about AgeMD’s physician-supervised longevity program →
Individual results may vary. This is not medical advice. Consult a licensed physician before starting any treatment program. All prescription peptide protocols at AgeMD require physician evaluation. Compounded medications are prepared by an FDA-registered pharmacy and are not FDA-approved drug products.
The February 2026 announcement is not just a regulatory correction. It reflects a broader shift in how HHS under Secretary Kennedy is approaching the intersection of patient access, clinical innovation, and regulatory oversight. For patients who have been tracking the longevity medicine space — who understand the difference between reactive disease management and proactive optimization — this is a meaningful signal.
The compounds returning to legal compounding status have decades of preclinical research and growing clinical evidence. Their restriction created an access gap that was filled by an unregulated market that served neither patient safety nor clinical outcomes. The reclassification does not resolve all scientific questions about these compounds — the lack of large-scale human trials remains a real limitation that physicians and patients should take seriously. But it does restore the appropriate setting for those questions to be answered: physician-supervised clinical practice, pharmacy-grade compounding, and longitudinal patient monitoring.
For patients waiting for access to physician-prescribed peptide protocols, the trajectory is clear. For those who have been using unregulated products and are now reconsidering, the path to safer access is becoming available. And for the broader project of longevity medicine — building a clinical practice that optimizes biology rather than reacting to disease — the return of these compounds to legitimate access is a step in the right direction.
AgeMD physicians approach every program the same way: with your biomarker panel, your clinical history, and a protocol built around what is actually happening in your body. When BPC-157 and related compounds formally return to legal compounding status, that will not change. What changes is that the tool is available again — used properly, under physician supervision, from a pharmacy that meets the quality standards your health deserves. Learn about AgeMD’s physician-supervised longevity program →
Individual results may vary. This is not medical advice. Consult a licensed physician before starting any treatment program. All prescription peptide protocols at AgeMD require physician evaluation. Compounded medications are prepared by an FDA-registered pharmacy and are not FDA-approved drug products.
For your longevity goals
Make longevity part of your everyday health plan
For your longevity goals
Make longevity part of your everyday health plan
For your longevity goals
Make longevity part of your everyday health plan
For your longevity goals
Make longevity part of your everyday health plan
FAQ: About BPC-157 Peptide
FAQ: About BPC-157 Peptide
Q1: Is BPC-157 legal right now in 2026?
As of this writing, the FDA has not yet formally published the updated Category 2 list following Secretary Kennedy's February 27, 2026 announcement. The announcement signals that reclassification is expected within weeks, but until the FDA publishes the formal change, compounding pharmacies are not yet authorized to compound BPC-157 under Section 503A. Patients should not source peptides from unregulated vendors solely based on the announcement. Monitor FDA.gov and work with a licensed physician for the current status.
Q2: Does Category 1 reclassification mean BPC-157 is FDA-approved?
No. These are entirely different designations. Category 1 status means a compound is eligible for use by licensed compounding pharmacies to prepare individualized medications under a physician's prescription. FDA approval requires successful completion of multi-phase clinical trials for a specific indication. BPC-157 has not completed that process and is not FDA-approved for any human indication. All compounded BPC-157 must be labeled: "Compounded by an FDA-registered pharmacy. Not an FDA-approved drug product."
Q3: Which specific peptides are expected to return to legal compounding status?
Based on the February 2026 HHS announcement and analysis from compounding pharmacy and regulatory experts, the peptides expected to return to Category 1 status include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, MOTS-C, and several others — approximately 14 of the original 19 restricted compounds. Approximately 5 peptides are expected to remain restricted. The FDA's formally published list will be the authoritative source when released.
Q4: Can I start or restart a BPC-157 protocol based on the announcement?
Not yet — and not without physician involvement regardless of regulatory timing. The formal reclassification has not yet been published by the FDA. Once it is, compounding pharmacies will require a valid physician's prescription to prepare and dispense BPC-157. Starting or restarting any peptide protocol requires a physician evaluation, appropriate lab work, and a clinical rationale. Sourcing from unregulated vendors, as announced, carries quality, purity, and legal risks that the reclassification is specifically designed to address through legitimate pharmacy channels.
Q5: How is AgeMD approaching the reclassification for existing and new patients?
AgeMD physicians are actively monitoring the FDA's formal publication timeline. When BPC-157 and related compounds formally return to Category 1 status, AgeMD physicians will evaluate clinical indication for each patient individually — based on their biomarker panel, clinical history, and protocol goals. No patient will be placed on a peptide protocol without a current physician evaluation. AgeMD partners exclusively with FDA-registered, accredited compounding pharmacies that meet USP 797 and 795 standards. Patients interested in learning whether peptide therapy may be appropriate for their protocol are encouraged to schedule a free consultation.
For general questions about AgeMD’s programs and process, visit our AgeMD FAQ page.
Q1: Is BPC-157 legal right now in 2026?
As of this writing, the FDA has not yet formally published the updated Category 2 list following Secretary Kennedy's February 27, 2026 announcement. The announcement signals that reclassification is expected within weeks, but until the FDA publishes the formal change, compounding pharmacies are not yet authorized to compound BPC-157 under Section 503A. Patients should not source peptides from unregulated vendors solely based on the announcement. Monitor FDA.gov and work with a licensed physician for the current status.
Q2: Does Category 1 reclassification mean BPC-157 is FDA-approved?
No. These are entirely different designations. Category 1 status means a compound is eligible for use by licensed compounding pharmacies to prepare individualized medications under a physician's prescription. FDA approval requires successful completion of multi-phase clinical trials for a specific indication. BPC-157 has not completed that process and is not FDA-approved for any human indication. All compounded BPC-157 must be labeled: "Compounded by an FDA-registered pharmacy. Not an FDA-approved drug product."
Q3: Which specific peptides are expected to return to legal compounding status?
Based on the February 2026 HHS announcement and analysis from compounding pharmacy and regulatory experts, the peptides expected to return to Category 1 status include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, MOTS-C, and several others — approximately 14 of the original 19 restricted compounds. Approximately 5 peptides are expected to remain restricted. The FDA's formally published list will be the authoritative source when released.
Q4: Can I start or restart a BPC-157 protocol based on the announcement?
Not yet — and not without physician involvement regardless of regulatory timing. The formal reclassification has not yet been published by the FDA. Once it is, compounding pharmacies will require a valid physician's prescription to prepare and dispense BPC-157. Starting or restarting any peptide protocol requires a physician evaluation, appropriate lab work, and a clinical rationale. Sourcing from unregulated vendors, as announced, carries quality, purity, and legal risks that the reclassification is specifically designed to address through legitimate pharmacy channels.
Q5: How is AgeMD approaching the reclassification for existing and new patients?
AgeMD physicians are actively monitoring the FDA's formal publication timeline. When BPC-157 and related compounds formally return to Category 1 status, AgeMD physicians will evaluate clinical indication for each patient individually — based on their biomarker panel, clinical history, and protocol goals. No patient will be placed on a peptide protocol without a current physician evaluation. AgeMD partners exclusively with FDA-registered, accredited compounding pharmacies that meet USP 797 and 795 standards. Patients interested in learning whether peptide therapy may be appropriate for their protocol are encouraged to schedule a free consultation.
For general questions about AgeMD’s programs and process, visit our AgeMD FAQ page.